Adaptive Biotechnologies Corp $ 42.23 -1.45 (-3.32%)
Volume:
2,017,594
Avg Vol (1m):
828,331
Market Cap $:
5.88 Bil
Enterprise Value $:
5.30 Bil
PE Ratio:
0.00
PB Ratio:
7.77
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 6.38 | ||
| Equity-to-Asset | 0.67 | ||
| Debt-to-Equity | 0.15 | ||
| Debt-to-EBITDA | -0.75 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 9.46 | ||
| Beneish M-Score | -2.81 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -155.33 | ||
| Net Margin % | -148.63 | ||
| ROE % | -23.06 | ||
| ROA % | -15.06 | ||
| ROC (Joel Greenblatt) % | -196.55 | ||
| 3-Year Revenue Growth Rate | 27.4 | ||
| 3-Year EBITDA Growth Rate | -45.5 | ||
| 3-Year EPS without NRI Growth Rate | -39.9 |
ADPT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 7.77 | ||
| PS Ratio | 56.51 | ||
| EV-to-EBIT | -34.68 | ||
| EV-to-EBITDA | -36.71 | ||
| EV-to-Revenue | 53.83 | ||
| Current Ratio | 6.91 | ||
| Quick Ratio | 6.78 | ||
| Days Inventory | 177.95 | ||
| Days Sales Outstanding | 37.27 | ||
| Days Payable | 52.44 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 9.43 | ||
| Earnings Yield (Greenblatt) % | -2.89 |